EcoDrugPlus

Natriuretic Peptide Receptor 2

Ensembl ID : ENSBTAG00000011434
Gene Symbol: NPR2
3 Enzyme and pathways 5 Cross references
272 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSBTAG00000007665
Gene Symbol: NPR3
4 Cross references
222 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSBTAG00000016633
Gene Symbol: NPY2R
7 Enzyme and pathways 5 Cross references
260 Possible Orthologues:

Neuropeptide Y Receptor Y5

Ensembl ID : ENSBTAG00000038421
Gene Symbol: NPY5R
7 Enzyme and pathways 5 Cross references
149 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSBTAG00000021727
Gene Symbol: NTSR1
7 Enzyme and pathways 5 Cross references
218 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSBTAG00000003060
Gene Symbol: NTRK1
12 Enzyme and pathways 5 Cross references
212 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSBTAG00000010647
Gene Symbol: NTRK2
8 Enzyme and pathways 5 Cross references
300 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSBTAG00000047543
Gene Symbol: NTRK3
10 Enzyme and pathways 5 Cross references
283 Possible Orthologues:

Nicastrin

Ensembl ID : ENSBTAG00000004334
Gene Symbol: NCSTN
17 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSBTAG00000015509
Gene Symbol: NAMPT
5 Enzyme and pathways 5 Cross references
247 Possible Orthologues:

Nischarin

Ensembl ID : ENSBTAG00000014779
Gene Symbol: NISCH
7 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSBTAG00000006894
Gene Symbol: NOS2
8 Enzyme and pathways 5 Cross references
178 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).